Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...2930313233343536373839...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): Final analysis of the FZOCUS-1 trial (Heidelberg Auditorium - Hall 6.2) -  Jul 24, 2025 - Abstract #ESMO2025ESMO_1617;    
    P3
    Grade >=3 TRAEs (mostly hematologic) were reported by 48.7%, 45.7%, and 7.4% of pts in the FZPL+APA, FZPL, and placebo group. Table: 1063O Efficacy summary FZPL+APA (N = 269) FZPL (N = 269) Placebo (N = 136) Overall population mPFS, mo (95% CI) 26.9 (20.3, 36.6) 29.9 (22.1, 36.1) 11.1 (8.3, 16.6) HR, vs placebo (95% CI) 0.57 (0.44, 0.75) 0.58 (0.44, 0.75) HR, vs FZPL (95% CI) 1.04 (0.83, 1.32) HRD, including BRCAm (n=486) mPFS, mo (95% CI) 34.1 (22.4, 41.2) 35.8 (27.3, NR) 16.6 (8.3, 31.1) HR, vs placebo (95% CI) 0.67 (0.48, 0.93) 0.62 (0.45, 0.87) HR, vs FZPL (95% CI) 1.09 (0.83, 1.44) HRP (n=118) mPFS, mo (95% CI) 16.6 (10.2, 22.1) 11.0 (6.5, 16.6) 5.5 (3.3, 13.8) HR, vs placebo (95% CI) 0.51 (0.30, 0.86) 0.68 (0.40, 1.15) HR, vs FZPL (95% CI) 0.73 (0.45, 1.19) Conclusions Adding antiangiogenic APA to FZPL did not enhance PFS among HRD pts in the 1L maintenance setting, while HRP pts showed PFS benefit trend with FZPL+APA compared to FZPL alone.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
    SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01) (Munich Auditorium - CityCube B) -  Jul 24, 2025 - Abstract #ESMO2025ESMO_1602;    
    P3
    Conclusions This chemo-free regimen of CAM plus FAM significantly prolongs PFS and OS compared with platinum-based chemo with/without bevacizumab as first-line treatment in pts with R/M CC, with a tolerable safety profile. Methods Taxane- and trastuzumab-pretreated patients (pts) with HER2+ advanced/metastatic BC were randomized (1:1) to receive intravenous SHR-A1811 or oral pyrotinib plus capecitabine...Results As of Jun 30, 2025, 287 pts were randomized (SHR-A1811, n=142; pyrotinib plus capecitabine, n=145; IHC 3+: 76.1% vs. 71.7%; HR+: 47.9% vs. 47.6%; median lines of prior systemic treatments: 1 vs.1; prior pertuzumab: 71.8% vs. 72.4%), with median follow-up of 15.9 months (95% CI 14.6
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Efficacy and Safety of Vunakizumab in Scalp Psoriasis :A Case Report of Three Patients (Poster Area) -  Jul 23, 2025 - Abstract #EADV2025EADV_5366;    
    P3
    These findings align with phase III trial data, supporting its role as a potent therapeutic option for recalcitrant scalp involvement. Larger studies are warranted to confirm long-term safety and durability.
  • ||||||||||  AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
    Refractory Palmoplantar Pustulosis Achieving Remission with Anti-IL-17A Agent Vunakizumab (Poster Area) -  Jul 23, 2025 - Abstract #EADV2025EADV_5266;    
    The patient remains on this therapeutic regimen, with ongoing follow-up to evaluate the treatment's long-term efficacy and safety. The treatment rationale for this case was informed by a randomized controlled trial which demonstrated the efficacy of an IL-17RA inhibitor, brodalumab, in PPP management.
  • ||||||||||  HXN-1011 / Earendil Labs
    AI-Guided Design and Development of HXN-1011: A Potent Anti-TSLP Biparatopic Antibody (Poster Area) -  Jul 23, 2025 - Abstract #EADV2025EADV_3047;    
    HXN-1011 is a next-generation biparatopic antibody exhibiting exceptional potency and holding significant potential to enhance clinical efficacy in the treatment of TSLP-driven inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), and other related indications. Preclinical studies and IND-enabling research for HXN-1011 are currently underway.
  • ||||||||||  Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, dasatinib / Generic mfg., voriconazole / Generic mfg.
    Review, Journal:  Pulmonary arterial hypertension caused by coadministration of dasatinib and voriconazole: A case report and literature review. (Pubmed Central) -  Jul 23, 2025   
    Despite recommendations to reduce the dasatinib dose to 20 to 40?mg daily for patients on voriconazole, the enhanced effect of dasatinib due to voriconazole coadministration may contribute to the development of pulmonary arterial hypertension. Regular echocardiography follow-up is essential for patients concurrently taking azole antifungal agents.
  • ||||||||||  imatinib / Generic mfg., Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
    Clinical, Observational data, Retrospective data, Journal:  Comparing therapeutic effects across tyrosine kinase inhibitors: Chronic myeloid leukemia outcomes and analysis of influencing factors. (Pubmed Central) -  Jul 23, 2025   
    Nilotinib and flumatinib demonstrate superior efficacy over imatinib, with effectiveness influenced by various factors including sociodemographic characteristics, clinical heterogeneity, and drug side effects. The proposed clinical prediction model may provide valuable insights for decision-making and demonstrates generalizability and practical application value.
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer () -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2564;    
    P3
    Twenty-four-point-four percent of patients in the ASTRUM-005 trial continued to receive serplulimab after disease progression, which may be one of the key factors contributing to a lower overall survival hazard ratio (HR) of non-head-to-head comparison to the IMpower133, CASPIAN, and CAPSTONE-1 trials (HR 0.62 vs 0.76, 0.71, 0.73, respectively)...The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Additional indicators include the relationship between T-cell subpopulation typing and number and therapeutic efficacy and the relationship between nutritional indicators and therapeutic effectiveness.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Efficacy and Safety of Adebrelimab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH) (Exhibit Hall Rows 28-36) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2041;    
    P2
    Primary endpoint is objective response rate.Secondary endpoints include overall survival (OS), 6-month OS rate, progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and safety. Exploratory endpoints include biomarker analysis, quality of life assessments, and long-term survivor characteristic.Trial registration: ChiCTR2400089170.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer (Exhibit Hall Rows 28-36) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2040;    
    The CAPSTONE-1 study established adebrelimab combined with carboplatin and etoposide as the first-line standard of care for patients with extensive-stage SCLC in China...Patients received induction therapy comprising adebrelimab (1200 mg q3w), apatinib (250 mg qd), and nab-paclitaxel (200 mg/m2 q3w) for 2-4 cycles, followed by maintenance therapy with adebrelimab and apatinib until disease progression or intolerable toxicity. The primary endpoint was ORR, the secondary endpoints included PFS, OS, disease control rate (DCR),duration of response and safety assessed by CTCAE v5.0.
  • ||||||||||  Cosela (trilaciclib) / Pharmacosmos
    Phase II Clinical Trial of Trilaciclib in Combination With PD-1 Inhibitor and Chemotherapy as First-Line Treatment for (NSCLC) (Exhibit Hall Rows 28-36) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2012;    
    P2
    grade 3 thrombocytopenia; Incidence of grade 3 anemia, etc.), safety and tolerability. Methods : Medication plan is Trilaciclib 240mg/m 2 intravenously for 30 minutes and administered within 4 hours before chemotherapy; Pembrolizumab 200mg Q3W; Or Camrelizumab 200mg Q3W; Or Tislelizumab 200mg Q3W; Or Sintilimab 200mg Q3W; Or Toripalimab 240mg Q3W; Pemetrexed (non-squamous cell carcinoma) is 500mg/m 2 Q3W; Paclitaxel Albumin-bound (squamous cell carcinoma) is 260mg/m 2 Q3W; Carboplatin is AUC=5, up to 750mg Q3W; At present, this study has passed the Medical Ethics Committee of Liaoning Cancer Hospital, and has completed registration in the Chinese Clinical Trial Registry, The registration number is ChiCTR2500098340.It is expected to take 12 months to complete the enrollment and 24 months to complete the study.
  • ||||||||||  AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
    A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitior for Treatment Na (Exhibit Hall Rows 28-36) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_2009;    
    Both cohorts will be treated until patients experienced disease progression, intolerable toxicity, or met the criteria for discontinuation of the trial drug. The primary endpoint of this trial is progression - free survival (PFS), while the secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
  • ||||||||||  The Mechanism of Immunotherapeutic Resistance in Pulmonary Sarcomatoid Carcinoma (Exhibit Hall Rows 23-25) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1938;    
    In humanized PDX models (Fig.1M), the CCR1/CCR5 inhibitor combination (G4) outperformed MIF inhibitor/ anti-TIGIT (G3) (Figs.1O-P), reversing resistance by increasing precursor-exhausted and reducing terminal-exhausted CD8+ T cells (Fig.1Q). These findings identify CCR1/CCR5 blockade as a novel strategy to reverse immunotherapeutic resistance in PSC Conclusions : The additional combination of CCR1/CCR5 blockade with anti-PD-1 demonstrated a synergistic efficacy to immunotherapy-resistant tumors via reshaping the microenvironment, potentially offering a novel approach to combat immunotherapy resistance in PSC.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit From Sequential Thoracic Radiotherapy and ICI in ES-SCLC (Exhibit Hall Rows 7-17) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1576;    
    P2
    Intriguingly, patients with either TMB-high or NE-like subtype features significant improvements in both PFS (n=33, HR=0.18, p=0.001) and OS (n=33, HR=0.12, p=0.017) with TRT. Conclusions : This study integrates Phase II and real-world data to identify biomarkers predicting long-term survival benefit from TRT and immune checkpoint inhibitors in ES-SCLC patients after treatment of etoposide/cisplatin and immune checkpoint inhibitors.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Efficacy of First-Line Treatment in Driver-Negative Non-Small Cell Lung Cancer With Liver Metastases : A Bayesian Network Meta-Analysis (Exhibit Hall Rows 12-20) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1386;    
    Among the 11 treatment strategies evaluated, the surface under the cumulative ranking curve of camrelizumab plus chemotherapy was 83.06% for PFS and 96.38% for OS. Conclusions : In treatment-naive patients with driver-negative NSCLC and liver metastases, the combination of a PD-1 inhibitor and chemotherapy provides greater benefits in terms of PFS and OS compared to chemotherapy alone, and camrelizumab plus chemotherapy may be an optimal treatment regimen.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Camrelizumab-Based Therapy-Induced RCCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials (Exhibit Hall Rows 12-20) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1348;    
    P3
    The CameL-sq study included patients with stage IIIB-IV squamous NSCLC receiving camrelizumab plus chemotherapy consisting of paclitaxel and carboplatin...Conclusions : This pooled analysis confirmed that RCCEP was relatively prevalent yet predominantly mild in severity among advanced NSCLC patients treated with camrelizumab-based regimens. Notably, the emergence of RCCEP positively correlated with enhanced efficacy, evidenced by improved ORR, prolonged PFS and OS, underscoring RCCEP as a potential predictive biomarker for therapeutic efficacy.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC (ePoster Lounge Station 4) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1167;    
    P2
    Although durvalumab consolidation has enhanced outcomes compared to traditional concurrent chemoradiotherapy (CRT), disease progression remains a formidable challenge...Patients were randomly assigned (1:1) to either an experimental regimen of induction immunotherapy and chemotherapy (two cycles of camrelizumab plus etoposide-platinum [EP] or etoposide-carboplatin [EC]) followed by CRT, prophylactic cranial irradiation (PCI), and up to 12 months of camrelizumab consolidation (camrelizumab group), or a control regimen of induction chemotherapy (EP or EC) followed by CRT and PCI (cCRT group)...Conclusions : These findings suggest that induction camrelizumab plus chemotherapy followed by CRT and camrelizumab consolidation may improve both PFS and OS in LS-SCLC without exacerbating toxicity. Further research to refine treatment sequencing could provide vital improvements in managing this challenging disease.
  • ||||||||||  Journal:  Treatment-related pure large-cell neuroendocrine carcinoma of the prostate with systemic metastases in a young adult: a rare case report. (Pubmed Central) -  Jul 22, 2025   
    After receiving 12 months of goserelin acetate, rezvilutamide and six cycles of docetaxel, the patient further underwent laparoscopic radical prostatectomy (LRP)...Subsequently, the patient then received immunotherapy with serplulimab (300 mg) and the EP regimen (combining etoposide and cisplatin) chemotherapy...Here we reported a rare case of treatment-related LCNEPC, who had experienced systematic therapy with comprehensive care. These diagnostic and therapeutic approaches may improve the management capability and highlight the critical role of multimodal strategies in the subsequent cases.
  • ||||||||||  Late Breaking Abstract - AI-guided biparatopic TSLP nanobody based TSLP/IL-4R? and TSLP/ST2 bispecific antibodies for chronic respiratory diseases (PS-30; Board Number: 4) -  Jul 22, 2025 - Abstract #ERS2025ERS_6955;    
    Epitope analysis validated an AI-guided biparatopic TSLP nanobody, exhibiting superior in vitro activity approximately 200-fold better than Tezepelumab, and also surpassing GSK5784283...It exhibited synergistic TARC inhibition in PBMCs and demonstrated superior anti-inflammatory effects in an OVA- induced asthma mouse model compared to Tezepelumab and Dupilumab...Similarly, the TSLP/ST2 BiAb matched the TSLP activity of the biparatopic nanobody and outperformed Astegolimab in ST2 activity of 10 times. The BiAbs derived from a best-in-class biparatopic TSLP nanobody hold significant promise for the treatment of asthma and COPD.